

Monoclonal Antibody Development

Solution for Small Molecules
and Challenging Targets



Monoclonal Antibody Development



We combine our proprietary DIANA-Ab single-cell technology for antibody screening and characterization with unique know-how in immunogen preparation to advance monoclonal antibody (mAb) development towards unprecedented affinity and selectivity against the most challenging targets, including **small molecules**.



Finding the best clone produced by immune system



Delivering pre-specified affinity and cross-reactivity requirements



Suitable for both diagnostics and research use




Highly customizable service with dedicated support

Mouse hybridoma monoclonal antibodies



Rabbit recombinant monoclonal antibodies



WHY RECOMBINANT ANTIBODIES?

- + Recommended for IVDR compliant immunoassays
- + Excellent scalability and lot-to-lot consistency
- + Simple species and isotype switching
- + Genetically stable - no drift (unlike hybridomas)

Phage display monoclonal antibodies




Rabbit polyclonal antibodies




WHY RABBIT ANTIBODIES?

- + High affinity and specificity for sensitive assays
- + High solubility and high thermal stability
- + Target a wider range of epitopes, including small molecules


Expertise in mAbs against Small Molecules



We achieve superior expertise in monoclonal antibodies against small-molecule antigens thanks to:



In-house
hapten
synthesis



Proprietary
bio-conjugation
know-how



DIANA-Ab
single-cell
screening

OPTIONAL OTHER SERVICES

ANTIBODY CONJUGATION

Fluorescent dyes
(including our panel of AF dyes)

DNA and RNA oligos
(in-house oligo synthesis)

Biotin and other tags

Nanoparticles

Proteins

ANTIBODY PRODUCTION

Small-to-mid scale
recombinant production

ANTIBODY ENGINEERING


Species switching
(including humanization)

Isotype and format switching
(Fab, scFv and more)

DIANA-Ab Technology: How Does It Work?


We utilize DIANA-Ab high-throughput screening (HTS) technology to search through the entire rabbit spleen clone repertoire ($\sim 10^9$ cells) and identify the best clones with superior affinity against your particular target.

DIANA-Ab PIPELINE




01 PLASMA CELL FACS SORTING

We use our proprietary secretion assay and FACS sorting to identify a small fraction of antigen-positive plasma cells: terminally differentiated B cells.




02 SINGLE-CELL DIANA-Ab SCREEN

With our ultra-sensitive DIANA-Ab HTS platform, both affinity (K_D) and cross-reactivity are quantified from a single cell (without any cultivation).




03 BEST CLONE SELECTION

Only the best clones are sequenced, cloned and expressed in HEK293 cells. Purified clones are further verified and ranked based on their properties and sequence diversity.



DIANA-Ab: Empowering AI with Wet-lab Data

We combine Mammalian cell display, AI tools and DIANA-Ab HTS technology for protein *de novo* engineering and maturation.



01 SINGLE-CELL DIANA-Ab SCREEN

- High-throughput screening of 5,000 – 10,000 cells per day
- Antibody-antigen K_D quantification
- K_D for up to 3 targets and off-targets
- Maintains genotype/phenotype linkage

02 AI-DRIVEN ANTIBODY PREDICTION

- DIANA-Ab quantitative data improves AI model
- Substantially lowers time and cost burdens of wet-lab screening
- Shortens development cycle

03 MAMMALIAN DISPLAY LIBRARY

- Contains solely AI generated clone sequences
- 1 gene per HEK293 or CHO cell
- Final Ab format in production cell type
- FACS for optional clone pre-selection based on affinity, cross-reactivity and developability



DIANA
BIOTECHNOLOGIES



www.dianabiotech.com



info@dianabiotech.com



vojtech.vyklicky@dianabiotech.com

DIANA Biotechnologies is a Czech biotech company that advances research and development. Powered by a team of top scientists in molecular biology, chemistry, pharmacology, and automation, we provide R&D services and products for academic labs, biotech companies, and pharmaceutical partners. Our offerings include the development of monoclonal antibodies, engineered PCR enzymes and drug discovery services.